KHR Biotec is a preclinical biopharmaceutical company with a strong commitment to help patients with unmet medical needs all over the world. As a spin-off of the University Medical Center Mainz, we aim to swiftly translate cutting-edge research into novel therapeutic tools towards precision medicine and personalized therapeutics. We aim to provide next generation therapeutics in oncology, autoimmune disorders, and infectious diseases.
One of our prime foci is to target the major oncogene “RAS (Rat Sarcoma),” which is mutated in a large number of human cancers. Based on our recent research success on oncogenic RAS, which was patented by Univ. Prof. Dr. Krishnaraj Rajalingam, we aim to quickly optimize and further develop small molecules for clinical use. Apart from targeting RAS molecules at the cell membrane, we further develop cancer therapeutics that efficiently inhibit “downstream” oncogenic signaling pathways.
KHR Biotec was established as a joint venture with the global oncology company Indivumed, which maintains the world’s most comprehensive cancer database. The partnership secures access to advanced AI analytics and extensive data from thousands of samples obtained under identical, highly standardized conditions. We combine rigorous inter-disciplinary approaches with Indivumed’s capabilities to bring new compounds targeting pertinent oncogenic signaling pathways into the clinical phase.
“Our long-standing research on cellular signaling pathways can now be used to individualize the treatment of cancer and other diseases.”
“We saw an opportunity to help the patients.”
Univ. Prof. Dr. Krishnaraj Rajalingam is one of the highly recognized experts in the field of molecular signaling pathways. As head of the Department of Cell Biology (CBU) at the University Medical Center Mainz, he has numerous research successes to his credit. In addition to his leadership role at CBU, he is a member of the Research Center for Immunotherapy (FZI) and the University Center for Tumor Diseases (UCT) at the University Medical Center Mainz. His research into cell signaling pathways provide the foundation for developing novel therapeutics.
Dr. Hajime Yurugi is the research lab team leader. Trained as a molecular cell biologist addressing pertinent questions in tumor biology and immunology, Hajime brings his rich experience in wet lab biology to KHR Biotec and aims to build a strong team to perform cutting-edge research with clear and explicit biomedical implications.
We are further supported and advised by a seasoned team of interdisciplinary experts who serve as advisors and consultants. More updates will be announced soon.
“An important step in translating successful basic research into practical, clinical applications for patients.”
As we are a brand-new company, this section has lots of room to grow. We are currently preparing our first product for transition into the clinical phase and plan to announce our first clinical results in 2022.
January 24, 2022 · Tagesschau
November 05, 2021 · Tagesschau
July 19, 2021 · Zeit Campus
May 19, 2021 · Press Release
“We are working to better understand and to develop treatments for RAS pathway mutations in cancer.”
We are hiring! Contribute your talent to our mission and join us in our quest to support precision oncology by developing innovative therapeutics for various cancers. We are currently looking for BTA/MTAs and PhD level Scientists in Biomedicine to strengthen our research team.
August 27, 2021
Business Address
KHR Biotec GmbH
Vorderdeich 7
21037 Hamburg, Germany
info@khrbiotec.com
Delivery Address
KHR Biotec GmbH
Building 911, Room 02-319
Obere Zahlbacher Straße 63
55131 Mainz